PMID-34215016 – Linaclotide for Chronic Constipation and IBS-C Meta-Analysis
Yang Y, Fang J, Liang J, et al. "Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation: a meta-analysis," Expert Rev Gastroenterol Hepatol, 2021;15(8):929-940.
Quick Reference
| Property | Value |
|---|---|
| PMID | 34215016 |
| DOI | 10.1080/17474124.2021.1944107 |
| Year | 2021 |
| Journal | Expert Rev Gastroenterol Hepatol |
| Study Type | Meta-Analysis |
| Evidence Level | I |
| Sample | 11 RCTs pooled, >7000 patients |
| Peptide(s) Studied | Linaclotide |
Key Findings
- Linaclotide was effective and safe for treatment of both chronic constipation (CC) and IBS-C compared to placebo
- Significant improvements in complete spontaneous bowel movement (CSBM) responder rates across all doses
- Significant reduction in abdominal pain scores in IBS-C trials
- Diarrhea was the most frequent adverse event but rarely led to discontinuation
- 290 mcg dose showed optimal risk-benefit profile for IBS-C; 145 mcg for CIC
- Overall adverse event rates were similar between linaclotide and placebo except for diarrhea
Study Design
Systematic review and meta-analysis of 11 RCTs identified through PubMed, Embase, and Cochrane Library. Included studies of linaclotide vs placebo in adult patients with CC or IBS-C. Primary outcomes were CSBM responder rate and abdominal pain improvement. Quality assessed using Cochrane Risk of Bias tool.
Limitations
- All included trials were industry-sponsored
- Duration limited to 12-26 weeks; long-term data not pooled
- Heterogeneity in outcome definitions across studies
- Geographic/ethnic variation limited (mostly Western populations)
Clinical Relevance
This updated meta-analysis confirms the consistent efficacy of linaclotide across a large patient pool with both CC and IBS-C. The dual benefit of improving bowel function and reducing abdominal pain distinguishes linaclotide from simple laxatives. The established safety profile supports chronic use. For clinicians, this meta-analysis provides the strongest level of evidence (Level I) for prescribing linaclotide as a first-line GC-C agonist.
Related
#research #meta-analysis #evidence-level-I #gastrointestinal #linaclotide